SuperworthTheriva Biologics TOVX
- Market cap
- $9M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Theriva Biologics' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | $300K | $0 | |
| R&D | $4M+56% | $4.2M+37% | $3.5M+16% | $3M−6% | $2.7M−32% | $2.9M−31% | $3M−14% | $2M−34% | $2.6M−7% | $1.1M−61% | $355K−88% | $1.3M−35% |
| SG&A | $212K−91% | $2M−52% | $1.9M−12% | $1.5M−45% | $2.3M+986% | $1.7M−16% | $1.4M−25% | $11.2M+662% | $1.9M−18% | $931K−45% | $2.1M+43% | $2M−82% |
| −$4.2M−15% | −$6.2M−15% | −$5.4M+4% | −$8.5M+46% | −$7.9M+87% | −$4.6M−26% | −$4.4M−18% | −$13.1M+55% | −$4.4M−44% | −$2.1M−55% | −$2.1M−52% | −$3.3M−75% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | $12K | $16K | n/a | n/a | $16K+33% | $17K+6% |
| Pre-tax income | −$3.8M−21% | −$5.9M−16% | −$5.2M+7% | −$8.3M+53% | −$7.7M+102% | −$4.4M−25% | −$4.3M−16% | −$13.1M+57% | −$4.4M−44% | −$2M−55% | −$2M−53% | −$3.2M−75% |
| −$527K+57% | −$424K−24% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$3.3M−26% | −$5.5M−15% | −$5.2M+15% | −$8.3M+64% | −$7.7M+134% | −$4.4M−19% | −$4.3M−16% | −$13.1M+57% | −$4.4M−44% | −$2M−55% | −$2M−53% | −$3.2M−75% |
| −$4.85−35% | −$8.04−22% | −$7.53+0% | −$10.72+26% | −$6.81+40% | −$1.60−80% | −$1.55−79% | −$1.93−82% | −$0.45−93% | −$0.12−93% | −$0.05−97% | −$0.07−96% | |
| 681.7K+8% | 682.5K+8% | 685.9K+13% | 775.7K+28% | 1.1M+66% | 2.8M+308% | 2.8M+306% | 6.8M+771% | 9.7M+753% | 29.1M+945% | 41.1M+1376% | 45.9M+580% |
EPS, diluted: 14 periods, Q4 FY11 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY11 and Q1 FY12: not printed by the filing, worked out from its own lines. 13 periods, Q4 FY11 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY17: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Theriva Biologics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| TOVXTheriva Biologics | $9M | n/m | n/a | n/m | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| Peer median | $64.6M | 10.1× | 9.5× | 0.9× | −12% | 9.2% |
More on Theriva Biologics
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .